Sodium-Glucose Cotransporter-2 Inhibitors; cardiovascular outcomes; renal outcomes; empagliflozin; Dapagliflozin; diabetes; heart failure; chronic kidney disease. Here, SLC5A2 is linked to diabetes mellitus.